Monocyte reprogramming for Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disease that leads to the progressive destruction of joints. The disease is not curable and requires life-long treatment.

Queen Mary researchers recently uncovered a novel family of specialised pro-resolving lipid mediators (SPM), termed as maresin conjugates in tissue regeneration (MCTR). MCTRs actively promote the resolution of inflammation by downregulating the production of pro-inflammatory soluble mediators and upregulating the formation of pro-resolving mediators. MCTRs also exert tissue reparative and regenerative activities. 

The novel therapy offers a rapid and simple approach using a proprietary molecule to transform patient monocytes, providing them with anti-inflammatory and tissue regenerative properties.

This innovative method not only identifies companion biomarkers for cell benchmarking but also holds promise for treating inflammatory conditions and reprogramming other therapeutic cells.